Teva Pharmaceutical Industries Ltd. (TEVA), an Israeli based company which was founded in 1901, develops and manufactures a variety of pharmaceuticals. They received approval from the U.S. Food and Drug Administration for AZILECT® (rasagiline tablets) as a treatment for Parkinson's disease. P/E is 54 and PEG is 1.1. The stock has been paying dividends quarterly and yields 1%.

Cell Genesys, Inc. (CEGE) is an investor in Ceregene, which developed CERE-120, its lead program for Parkinson's disease. Earnings for CEGE are negative and the price sales ratio is an extremely high 225.

Novartis AG (NVS), a very large Swiss pharmaceutical company, has developed Comtan® (entacapone), a medication for the treatment of Parkinson's Disease. P/E is 19 and the PEG is 1.5. Yield is 1.6%.

Acadia Pharmaceuticals Inc. (ACAD), based in San Diego, is working on ACP-103 in patients with Parkinson's disease suffering from treatment-induced psychosis. Negative earnings, P/S of 53.

Sanofi-Aventis (SNY) is the third largest pharmaceutical company in the world. It is working on SR57667B for treatment of symptoms. PE IS 23, PEG is 2.3. Yield is 2.1%.

SkyePharma plc (SKYE) developed once-daily formulation of Requip® utilizing SkyePharma's Geomatrix™ technology. Requip is used for Parkinson's treatment. No earnings, P/S is 3.5.

Valeant Pharmaceuticals International (VRX) markets Zelapar® [selegiline HCl] Orally Disintegrating Tablets, a once-daily adjunct therapy for Parkinson’s disease patients being treated with levodopa/carbidopa. Forward P/E of 16.6 and a PEG of .8. Yields 1.7%.